• Serve as an educational resource and platform for EU policymakers to increase awareness of evidence-based psychedelic science and decrease associated stigma.

​

• Promote pan-European scientific cooperation and best practices at the EU Member State level.

​

• Organize periodic meetings and issue policy recommendations.

​

• Foster EU-funded research to meaningfully increase the scientific and clinical evidence supporting the safe, effective, and efficient use of psychedelic medicines.

​

• Safeguard optimal care and safety for patients while promoting meaningful engagement of people with lived experience.

​

• Ensure that the development of psychedelic treatments is guided by public health benefit.

​

• Advocate for a harmonized EU policy and regulatory framework for psychedelic therapies and a predictable environment for both patients and providers.

​

• Provide input to ongoing legislative discussions and negotiations in the EP.

​

• Promote drug policies based on scientific evidence and human rights to remove the barriers weighing on the scientific research of psychedelics and accelerate access.

​

• Make Europe an innovation leader and a global regulatory benchmark in this area.

​

​